---
figid: PMC9254480__ijbsv18p3845g001
pmcid: PMC9254480
image_filename: ijbsv18p3845g001.jpg
figure_link: /pmc/articles/PMC9254480/figure/F1/
number: Figure 1
figure_title: ''
caption: The VEGF-VEGFR signaling pathway. VEGF-A binds to VEGFR-2 for dimerization,
  autophosphorylation, and activation leading to endothelial cell survival, proliferation,
  permeability, and migration. mTOR, mammalian target of rapamycin; MAPK, mitogen-activated
  protein kinase; MEK, MAP kinase kinase.
article_title: 'VEGF/VEGFR-Targeted Therapy and Immunotherapy in Non-small Cell Lung
  Cancer: Targeting the Tumor Microenvironment.'
citation: Yueshui Zhao, et al. Int J Biol Sci. 2022;18(9):3845-3858.
year: '2022'

doi: 10.7150/ijbs.70958
journal_title: International Journal of Biological Sciences
journal_nlm_ta: Int J Biol Sci
publisher_name: Ivyspring International Publisher

keywords:
- NSCLC
- tumor microenvironment
- VEGF/VEGFR pathway
- immunotherapy
- clinical trials

---
